Hrain Biotechnology

Developer of tumor immunotherapy technology

placePudong, Shanghai, China calendar_todayFounded 2015 groups260 employees language dashengbio.com

Innovation

22 patent families (8 granted) — focus: Chemistry & metallurgy, Human necessities; filing pace slowing. Cited 127 times.

YearFilings
20202
20219
20221
20239
20243
20253
20261

Investor mix

5 investors on record; lead investors include Qiming Venture Partners, Yingke Capital, Shenzhen Capital Group.

Investor typeCountShare
Venture capital360%
Private equity120%
Other / undisclosed120%
Coming soon